EN | RU
EN | RU

Help Support

Back

Oral merimepodib to be tested for COVID-19 treatment

Oral merimepodib to be tested for COVID-19 treatment Oral merimepodib to be tested for COVID-19 treatment
Oral merimepodib to be tested for COVID-19 treatment Oral merimepodib to be tested for COVID-19 treatment

What's new?

Merimepodib oral may be the new hope for the treatment of coronavirus.

After the authorization of an Investigational New Drug Application by the FDA as announced on 18 May, 2020, the new pharmaceutical subsidiary has declared that a randomized, double-blind phase 2 study will be started assessing merimepodib oral solution for coronavirus disease 2019 (COVID-19) treatment. 

Merimepodib is an antiviral drug with proven efficacy in preclinical study against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Merimepodib when used alone or along with remdesivir, was linked with a substantial decrease in viral production in cell cultures as per the results of a study anticipating peer review. 

The phase 2 study will compare the safety and efficacy of merimepodib to placebo in hospitalized adult, COVID-19 patients who are either on non-invasive ventilation/high flow oxygen devices or are in need of additional oxygen. As expected, this study will be performed at various sites in the US.

Source:

BioSig

Article:

Antiviral Merimepodib to Be Investigated in Phase 2 Trial for COVID-19

Comments (0)

Recommendations

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: